RAPT Therapeutics, Inc. (NASDAQ:RAPT) Given Consensus Recommendation of "Hold" by Analysts

RAPT Therapeutics, Inc. (NASDAQ:RAPT - Get Free Report) has been given an average rating of "Hold" by the nine analysts that are currently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating and two have assigned a buy rating to the company. The average 1 year price objective among analysts that have covered the stock in the last year is $5.29.

Separately, HC Wainwright restated a "buy" rating and issued a $10.00 target price on shares of RAPT Therapeutics in a report on Monday, March 10th.

RAPT Therapeutics Price Performance

Shares of NASDAQ:RAPT traded up $0.11 during trading on Thursday, reaching $1.31. 4,666,384 shares of the stock were exchanged, compared to its average volume of 1,250,901. RAPT Therapeutics has a 1-year low of $0.79 and a 1-year high of $9.65. The stock has a fifty day moving average of $1.17 and a two-hundred day moving average of $1.48. The firm has a market cap of $172.93 million, a price-to-earnings ratio of -0.47 and a beta of -0.31.

RAPT Therapeutics (NASDAQ:RAPT - Get Free Report) last released its quarterly earnings data on Thursday, March 6th. The company reported ($1.14) earnings per share for the quarter, missing the consensus estimate of ($0.45) by ($0.69). Sell-side analysts forecast that RAPT Therapeutics will post -2.14 EPS for the current year.

Institutional Trading of RAPT Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in RAPT. Trustees of Columbia University in the City of New York bought a new stake in RAPT Therapeutics in the 4th quarter worth about $116,000. Shay Capital LLC purchased a new position in shares of RAPT Therapeutics in the 4th quarter worth approximately $81,000. RTW Investments LP bought a new position in shares of RAPT Therapeutics in the fourth quarter valued at approximately $18,587,000. Redmile Group LLC increased its position in shares of RAPT Therapeutics by 1,183.4% during the fourth quarter. Redmile Group LLC now owns 6,475,317 shares of the company's stock valued at $10,231,000 after acquiring an additional 5,970,785 shares during the last quarter. Finally, Nuveen Asset Management LLC increased its position in shares of RAPT Therapeutics by 50.5% during the fourth quarter. Nuveen Asset Management LLC now owns 116,925 shares of the company's stock valued at $185,000 after acquiring an additional 39,216 shares during the last quarter. Hedge funds and other institutional investors own 99.09% of the company's stock.

About RAPT Therapeutics

RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.